Bioventus (NASDAQ:BVS) Given New $19.00 Price Target at Canaccord Genuity Group

Bioventus (NASDAQ:BVS) had its price target raised by equities researchers at Canaccord Genuity Group from $15.00 to $19.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target points to a potential upside of 33.24% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Barrington Research set a $18.00 price objective on Bioventus in a report on Thursday, August 6th. Craig Hallum reaffirmed a “buy” rating and issued a $18.00 price target on shares of Bioventus in a research note on Thursday, August 6th. Weiss Ratings raised Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, August 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 target price on shares of Bioventus in a research note on Monday. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $16.80.

Bioventus Price Performance

Shares of NASDAQ BVS opened at $14.26 on Monday. The business’s 50 day moving average price is $11.36 and its 200 day moving average price is $9.91. The firm has a market cap of $1.20 billion, a P/E ratio of 18.52, a P/E/G ratio of 1.82 and a beta of 0.63. Bioventus has a 52 week low of $6.26 and a 52 week high of $15.89. The company has a quick ratio of 1.17, a current ratio of 1.69 and a debt-to-equity ratio of 0.83.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.22. The company had revenue of $153.21 million during the quarter. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, sell-side analysts expect that Bioventus will post 0.79 earnings per share for the current year.

Institutional Investors Weigh In On Bioventus

A number of institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Bioventus by 17,156.2% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock worth $41,000 after acquiring an additional 5,490 shares during the last quarter. Prelude Capital Management LLC purchased a new position in shares of Bioventus during the third quarter worth $74,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Bioventus in the third quarter valued at $78,000. Brooklyn Investment Group purchased a new stake in shares of Bioventus in the 4th quarter valued at $91,000. Finally, Truist Financial Corp acquired a new position in Bioventus during the 4th quarter worth about $93,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.